© 2022 Regional Cancer Care Associates. All rights reserved.
A Phase 1/2 Study Of Tpx-0131, A Novel Oral Alk Tyrosine Kinase Inhibitor In Subjects With Alk+ Advanced Or Metastatic Nsclc Read more
A Phase 2 Study Of VS-6766 (Dual RAF/MEK Inhibitor) As A Single Agent And In Combination With Defactinib (FAK Inhibitor) In Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC) Read more
An Open-Label, Multicenter Phase I Dose Escalation Study To Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics And Maximum Tolerated Dose Of VIP152 (BAY 1251152) In Subjects With Advanced Cancer Read more
An expanded access protocol for mobocertinib in refractory Non-Small Cell Lung Cancer patients with EGFR exon20 insertion mutations Read more
A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer Read more
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Of Pembrolizumab (MK-3475) In Combination With Concurrent Chemoradiation Therapy Followed By Pembrolizumab With Or Without Olaparib (MK-7339), Compared To Concurrent Chemoradiation Therapy Alone In Participants With Actively Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) Read more
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation Read more
Prospective Collection Of Donor Tissue And Blood Or Leukapheresis Product From Patients With Solid Tumours To Enable Development Of Methods For The Manufacturing Of Clonal Neoantigen T Cell Products (Cnet) Read more
